Government Implements Rs. 15,000 Crore Production Linked Incentive Scheme For Pharmaceuticals
By Iednewsdesk On Aug 2, 2024
Share
The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore and scheme tenure up to FY 2027-28. The scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years. The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc. Orphan drugs are those drugs which are used for treatment of rare diseases. Under the scheme, total 8 orphan drugs have been approved for manufacturing. The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:
S. No. Name of the product Usage
1 Nitisinone Treatment of Hereditary Tyrosinemia Type 1
2 Nusinersen Treatment of Spinal Muscular Atrophy
3 Rufinamide Treatment of Lennox-Gastaut syndrome.
4 Sodium Phenyl Butyrate Treatment of Urea Cycle Disorders
5 Tiopronin Prevention of Cystine Nephrolithiasis
6 Trientine Hydrochloride Treatment of Wilson’s disease
7 Eliglustat Treatment of Gaucher’s disease
8 Cannabidiol Treatment of Dravet-Lennox Gastaut syndrome
https://chat.whatsapp.com/Iili8jkCHeYJYi3x89OPuF
